AstraZeneca’s US$1.5 billion manufacturing
plant to create over 800 jobs in Singapore
- AstraZeneca will hire over 800 employees for its new US$1.5 billion facility in Tuas South, Singapore
- The facility will be operational by 2029 and will produce antibody drug conjugates (ADCs) for cancer treatment
- It will be AstraZeneca’s first end-to-end ADC production site globally
- AstraZeneca’s ADC technology targets various cancers, including breast, ovarian, and endometrial cancers
- The facility will be designed to emit zero carbon from day one, supporting Singapore’s sustainability goals
AstraZeneca plans to hire over 800 employees in Singapore for various roles, including engineering and global supply chain positions, at its new US$1.5 billion manufacturing facility in Tuas South. The facility, covering 23 hectares, will be AstraZeneca’s largest investment and is expected to be operational by 2029. It will produce antibody drug conjugates (ADCs), a type of cancer treatment that delivers chemotherapy directly to cancer cells, minimizing damage to healthy cells.
This facility will be AstraZeneca’s first site worldwide to handle the entire process of ADC production, which includes creating antibodies, synthesizing chemotherapy drugs, and combining them. ADCs are designed to target cancer cells more effectively than traditional chemotherapy.
The facility will also be environmentally sustainable, with plans to have zero carbon emissions from day one. This aligns with Singapore’s goal of achieving net-zero emissions by 2050. The new facility will contribute to Singapore’s growing biopharmaceutical sector and support the development of precision medicines. AstraZeneca has six ADCs in its portfolio and many more in development, targeting various types of cancer.
Read the full article: AstraZeneca’s US$1.5 billion manufacturing plant to create over 800 jobs in Singapore
